uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V. reported first quarter 2026 results showing a net loss of $53.5 million, or $0.85 per share, compared with a $43.6 million loss a year earlier. Revenue rose to $3.6 million from $1.6 million, mainly from higher license revenue.
The company ended March 31, 2026 with $586.6 million in cash, cash equivalents and current investment securities and expects this to fund operations into the second half of 2029. Research and development expenses fell to $29.2 million, while selling, general and administrative expenses increased to $20.1 million, reflecting hiring for AMT-130 commercial planning.
uniQure highlighted pipeline progress, including ongoing FDA interactions for AMT-130 in Huntington’s disease with a Type B meeting planned in the second quarter of 2026 and a targeted UK marketing authorization application submission in the third quarter of 2026. Additional 2026 updates are expected from AMT-260 in mesial temporal lobe epilepsy, AMT-191 in Fabry disease and AMT-162 in SOD1 ALS.
Aberdeen Group plc and abrdn Inc. report beneficial ownership of 5,306,386 ordinary shares of uniQure N.V., representing 8.49% of the class. The filing states shared voting and dispositive power for 5,306,386 shares. The disclosure is submitted by a parent and intermediate holding structure and signed by a Major Shareholding Reporting Analyst on 03/31/2026.
uniQure N.V. announced a successful pre-submission meeting with the UK Medicines and Healthcare products Regulatory Agency for AMT-130, its investigational gene therapy for Huntington’s disease. The company plans to submit a UK Marketing Authorization Application in the third quarter of 2026.
The planned submission will be based on three-year data from ongoing U.S. and European Phase I/II trials, where high-dose AMT-130 showed a statistically significant 75% slowing of disease progression on a composite Huntington’s scale versus a matched external control (p=.003) and was generally well-tolerated with a manageable safety profile.
uniQure has also been granted a Type B meeting with the U.S. Food and Drug Administration in the second quarter of 2026 to discuss a potential Phase III trial design and the statistical analysis plan for a four-year data readout expected in the third quarter of 2026, while pursuing additional ex-US regulatory pathways.
uniQure N.V. is asking shareholders to vote at its 2026 Annual General Meeting on June 10, 2026 in Amsterdam on financial statements, director reappointments and several governance and capital proposals.
Key items include adopting the 2025 Dutch statutory annual accounts, granting discharge to board members, reappointing three non-executive directors, and appointing KPMG Accountants N.V. as external auditor for 2026. The board seeks authority for 18 months to issue up to 12,400,000 ordinary shares, to limit or exclude pre-emptive rights on those issuances, and to repurchase up to 10% of issued share capital. Shareholders are also asked to approve, on an advisory basis, 2025 executive pay and to hold future “say‑on‑pay” votes every year, amend and restate the 2014 Share Incentive Plan with an additional 350,000 shares (bringing total plan capacity to 11,040,279 shares), and approve several amendments to the Articles of Association, including adopting the Dutch large company regime, increasing authorized share capital and adding a federal forum selection clause. Record date is May 13, 2026, with approximately 63,065,985 ordinary shares entitled to one vote each; the board recommends voting “FOR” all proposals and “ONE YEAR” on say‑on‑pay frequency.
uniQure N.V. convenes its 2026 Annual General Meeting on June 10, 2026 to vote on routine Dutch-law items and governance actions, including adoption of the 2025 Dutch statutory annual accounts, discharge of the Board, reappointments of three non-executive directors, authorizations to issue up to 12,400,000 ordinary shares (approx. 19.7%), authority to exclude or limit pre-emptive rights, an 18‑month share repurchase authorization up to 10% of issued capital, appointment of KPMG as auditor, and an amendment to the 2014 Share Incentive Plan increasing the reserve to 11,040,279 shares. The record date is May 13, 2026, and approximately 63,065,985 Ordinary Shares were expected outstanding as of that date.
uniQure N.V. reported that Chief Customer & Strategy Officer Kylie O'Keefe received new equity awards. On March 4, 2026, she was granted stock options for 31,900 shares at an exercise price of $0.00 per share and 19,800 ordinary shares as restricted share units.
The restricted share units vest in three equal annual installments of one-third each, starting on the first anniversary of the grant date, subject to her continued relationship with the company. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested, also contingent on continued service.
uniQure N.V. executive Kylie O'Keefe filed an initial ownership report, showing existing equity awards in the company. The filing lists 180,000 stock options and 105,000 Ordinary Shares held directly as of the reporting date. Footnotes explain that these positions arise from prior equity grants that vest over time.
Restricted share units granted on June 11, 2025 convert into Ordinary Shares in three equal annual installments, subject to continued service. A stock option granted the same day vests over four years, with 25% vesting after one year and the remainder vesting quarterly until June 11, 2029, also contingent on continued service.
uniQure N.V. CEO and managing director Matthew C. Kapusta reported new equity compensation grants and a small related share sale. He was granted stock options for 113,800 shares at an exercise price of $0.00 per share and 70,600 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments beginning on the first anniversary of the grant date, subject to his continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested. In a separate transaction, 14,581 ordinary shares were sold at a weighted average price of $9.06 per share, within a range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.